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THROMBOTIC THROMBOCYTOPENIC PURPURA FOLLOWING BONE 
MARROW TRANSPLANT TREATMENT AND OUTCOME IN TEN 
PATIENTS 
Peres, E.M.; Abella, E.; Damey, R. Stem cell Tmmplam, K~Trmanos 
Cancer Institute, Detroit, MI. 
Severe thrombotic thrombocytopenic purpura OH'P) requiring 
intervention is a serious complication following bone marrow 
transplant (BMT). The therapeutic modalities (unlike classic T IP )  
are limited since therapeutic plasma exchange has a very poor 
response. BMT TTP is usually associated with cyclosporine, total 
body irradiation or other medications. A total of 10 patients who 
underwent BNIT were diagnosed with severe TTP  during 1996- 
2001 age range 5-58 (mean 27.2). The diagnosis was made based on 
the criteria of thrombocytopenia, microhemangiopathic emolytic 
anemia, elevated LDH mean 5012 (range 4672-9232) and schisto- 
cytes on the peripheral smear. Of the 10 patients, 2 were treated 
with plasma exchange (20%), and 9 patients were treated with sup- 
portive care and the discontinuation f cyclosporine (90%). Of the 
10 patients 9 were allogeneic bone marrow transplants 5 being 
MUD (50%) all patients except i were receiving cyclosporine at 
the time of diagnosis. Outcome: mortality was 100% in all patients 
treated with and without plasma exchange. There appears to be no 
benefit of plasma exchange in patients with severe TTP  after BMT 
and an improved understanding of the pathogens i and treatment 
of this complication is currently needed. 
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A FLUORESCENCE-BASED ASSAY SUITABLE FOR MONITORING NR 
ACTIVITY IN CLINICAL SETTINGS 
Sto~wls, R. V~I; Gree~z, P.D/; Chao, N.J/; Smitt,, C,4.2; Nikcevieh, 
D.AJ 1. Departmem of Medicim, Dzdee U~tiversity 3ledical Cemer, 
Din'ham,, NC; 2. Moffitt Cmzcer Cemer, Tampa, FL. 
Natural killer (NK) cells are increasing important within the con- 
text of cellular therapies, to include allogeneic bone marrow trans- 
plantafion and donor lymphocyte infilsions. Historically, 51Cr release 
has been the standard hz vitro measurement for NK activity. Howev- 
er, qCr release has pour sensitivity for NK activity if effector cell 
numbers are limiting and patients undergoing allogeneic transplanta- 
tion frequently have very low blood cell counts. To support our on- 
going clinical protocols in allogeneic bone marrow transplantation, 
we have developed a fluorescence-based assay to monitor NIL func- 
tion that is accurate ven with limiting effector cell numbers. In this 
assay the target cells are labeled with carbo .xyfluorescein diaeetate suc- 
cinimydyl ester (CFSE). After incubations with NK cells, the kilting 
of target cells is monitored by their membrane permeability asdetect- 
ed with the nucleic acid stain 7-amino actinomycin D (TAAD). In par- 
allel assays, the CFSE-based assay generated dose-response curves 
similar to those achieved with SlCr release assays. However, the fluo- 
rescence-based assay remained sensitive at lower target cell numbers 
where the results of 51Cr-release assays were not interpretable. As 
would be anticipated, an immtmomagnetic selection of CD56 + ceils 
greatly increased the sensitivity of the assay. More importantly, with 
CD56+-selected ceils as effectors the CFSE-based lysis assay yields 
classic sig~oidal dose-response curves in assays performed in as little 
as one hour. Finally, we note that with this combination of fluores- 
cent dyes file samples can be fixed with formaldehyde and processed 
at a later time. Taken together, these data demonstrate his fluores- 
cence-based lysis assay issensitive, asy to conduct and time effective, 
yet the materials are inexpensive, making it suitable for clinical use. 
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NMDP MARROW COLLECTION CENTER EXPERIENCE AND ITS EFFECT 
ON CELL CONCENTRATION AND CELL DOSE 
Robit~ett, Pff. l; Simm; P. I; Hemlan, ft. 2; Karanes, C.1; Kelwalz, N.A. 3; 
Lymh, ff.p.4; Pvzepiorka, D. % Ubevti, ff /; Welte, IC ~ I. NMDP, Min- 
neapolis, 3/1N," 2. Thomas Jefferson U~ziversity Hospitals, Philadelphia, 
Rk 3. 3/lemorial Sloan Ketteri~zg Career Center, New York, NY," 
4. Saint Fmmis Hospital, Tul~:a, OK; 5. University of Tennessee, Mem- 
phis, TN," 6. University of Michigan Meckbal Ceme'r, Amz Arbor, 3/11. 
As increasing numbers of unrelated onor stem cell transplants 
utilize peripheral blood stem cells (PBSC), physicians are per- 
forming fewer marrow collections. The National Marrow Donor 
Program (NMDP) evaluated ata from its collection centers to 
determine if there were differences in marrow cellularity or donor 
morbidity based on the marrow collection experience of the col- 
lection center. NMDP collection centers (n=97) were divided into 
tbur groups, based on the nmnber of NMDP marrow collections 
performed at the center in 2001. Each group performed appro~ 
mately 25% of all NMDP marrow collections (n=926) in 2001. 
Group 1 centers each performed _>24 NMDP collections, group 2 
between 16 and 23, group 3 between 8 and 15 collections, and 
group 4 performed <7 collections in 2001. The median cell dose 
(x 10S/kg recipient weight) and median nucleated ceil concentra- 
tion (x 106/ml) were compared among groups using a median test. 
There was no significant difference in the median cell dose among 
the four groups of centers, however there was a borderline signifi- 
cant difference (P-value = 0.02) among median cell concentra- 
tions, where group 2 had a slightly higher median cell concentra- 
tion than the other groups. The incidence of severe (very intense, 
prolonged or excruciating) donor post-donation complication 
rates reported by NMDP donor centers was also compared. There 
were no significant differences among groups 1, 2, 3 and 4 at 
0.5%, 1%, 2% and 2% respectively. In conclusion, NMDP data 
do not appear to indicate that collection centers with less marrow 
collection experience produce less cellular products or result in 
increased onor morbidity. 
Group CentelS il  ~c~INM# of NMDP Median Cell p Valtle Median Cell 
Group Collections Do~c Concentration 
i 7 D e 12 :! 0,0 22~ 
I 229 4.1 244 
3 23 262 ] 36 220 
4 56 216 ] 4O 232 
P-Value 
002 
7O 
FACTORS ASSOCIATED WITH AMBIVALENCE ABOUT BONE MAR- 
ROW DONATION AMONG NEWLY RECRUITED UNRELATED POTEN- 
TIAL DONORS 
Switze~% G.E.; Myaskovsky, L.; Goycoolea, J.M.; Dew, ~i. Medickze, 
University of Pittsbm-gh Medical Cemer, Pittsburgh, PA. 
Our previous research indicated that feelings of ambivalence or 
reluctance about donation were associated with donors' decisions 
not to donate, and with less positive physical and psychosocial 
outcomes among donors who donated espite feeling ambivalent. 
The current study examines the prevalence of ambivalence among 
newly recruited potential bone marrow donors, and identifies fac- 
tors associated with greater ambivalence. Using a cross-sectional 
design, questionnaires were mailed to a stratified random sample 
of individuals newly recruited to the NMDP registry at 71 local 
donor centers. 426 (63%) of new recruits completed and returned 
the questionnaire. Bivariate analyses indicated that multiple 
recruimmnt experience and donor perception variables were sig- 
nificantly associated with ambivalence. Multivariate analysis 
revealed that eight variables - -  participating in other volunteer 
activities (p<.05), joining at a drive for a specific patient (p<.05), 
perceiving the recruitment s aff as less informative (p<.001), being 
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